The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Cancer Research

• Publication date

  1999-09-01

• Fields of study

  Medicine

• Identifiers
  PMID 10485454
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy.

  1999influential reference
• Interaction of an Adenovirus E3 14.7-Kilodalton Protein with a Novel Tumor Necrosis Factor Alpha-Inducible Cellular Protein Containing Leucine Zipper Domains

  1998cited by this paper
• Methods of gene delivery.

  1998cited by this paper
• Prostate Cancer

  1998cited by this paper
• Adenovirus death protein, a transmembrane protein encoded in the E3 region, is palmitoylated at the cytoplasmic tail.

  1998cited by this paper
• The adenovirus E3/10.4K-14.5K proteins down-modulate the apoptosis receptor Fas/Apo-1 by inducing its internalization.

  1998cited by this paper
• Cancer statistics, 1998

  1998cited by this paper
• A Randomised Comparison of ‘Casodex’TM (Bicalutamide) 150 mg Monotherapy versus Castration in the Treatment of Metastatic and Locally Advanced Prostate Cancer

  1998cited by this paper
• Relative activity and specificity of promoters from prostate‐expressed genes

  1998cited by this paper
• A Membrane Setting for the Sorting Motifs Present in the Adenovirus E3-13.7 Protein Which Down-regulates the Epidermal Growth Factor Receptor*

  1998cited by this paper
• Viral vectors for gene therapy.

  1998cited by this paper
• Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression.

  1997cited by this paper
• Adenovirus E3-10.4K/14.5K protein complex inhibits tumor necrosis factor-induced translocation of cytosolic phospholipase A2 to membranes

  1997cited by this paper
• Large fragment of the probasin promoter targets high levels of transgene expression to the prostate of transgenic mice

  1997cited by this paper
• Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells.

  1997influential reference
• Prostate-specific Antigen Expression Is Regulated by an Upstream Enhancer (*)

  1996cited by this paper
• The E3-11.6-kDa adenovirus death protein (ADP) is required for efficient cell death: characterization of cells infected with adp mutants.

  1996cited by this paper
• The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells

  1996cited by this paper
• E3 transcription unit of adenovirus.

  1995cited by this paper
• The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice.

  1994cited by this paper
• An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3.

  1994cited by this paper
• Identification of class I MHC regions which bind to the adenovirus E3-19k protein.

  1994cited by this paper
• Down-regulation of HLA antigens by the adenovirus type 2 E3/19K protein in a T-lymphoma cell line

  1994cited by this paper
• Adenoviruses as expression vectors and recombinant vaccines.

  1990cited by this paper
• Role of early region 3 (E3) in pathogenesis of adenovirus disease.

  1989cited by this paper
• Cancer statistics

  1989cited by this paper
• Development of a helper-independent human adenovirus vector and its use in the transfer of the herpes simplex virus thymidine kinase gene

  1986cited by this paper
• Human adenovirus cloning vectors based on infectious bacterial plasmids.

  1986cited by this paper
• Tn5 mutagenesis of the transforming genes of human adenovirus type 5.

  1982cited by this paper
• Characteristics of a human cell line transformed by DNA from human adenovirus type 5.

  1977cited by this paper

• State-of-the-art in oncolytic virotherapy using adenoviruses other than the commonly applied adenovirus type 5.

  2025cites this paper
• PSA inhibitors for contraception: insights from prostate cancer.

  2025cites this paper
• Synergy of oncolytic adenovirus and immune checkpoint inhibitors: transforming cancer immunotherapy paradigms

  2025cites this paper
• Development and Characterization of an Oncolytic Human Adenovirus-Based Vector Co-Expressing the Adenovirus Death Protein and p14 Fusion-Associated Small Transmembrane Fusogenic Protein

  2024cites this paper
• Role of homologous recombination/recombineering on human adenovirus genome engineering: Not the only but the most competent solution

  2024cites this paper
• Polymeric Systems for Cancer Immunotherapy: A Review

  2022cites this paper
• Oncolyic Virotherapy for Prostate Cancer: Lighting a Fire in Winter

  2022cites this paper
• The genome position of a therapeutic transgene strongly influences the level of expression in an armed oncolytic human adenovirus vector.

  2021cites this paper
• Considering the potential for gene-based therapy in prostate cancer

  2021cites this paper
• Concepts in Oncolytic Adenovirus Therapy

  2021cites this paper
• Expanding the Spectrum of Adenoviral Vectors for Cancer Therapy

  2020cites this paper
• The Effect of PEI-Mediated E1A on the Radiosensitivity of Hepatic Carcinoma Cells

  2020cites this paper
• Constructing Gene‐Enhanced Tissue Engineering for Regeneration and Repair of Osteochondral Defects

  2019cites this paper
• Comparison of infectivity and spread between HSV-1 and HSV-2 based oncolytic viruses on tumor cells with different receptor expression profiles

  2018cites this paper
• Enhancing Oncolytic Adenovirus Vector Efficacy through Co-expression of the p14 Fusion-associated Small Transmembrane Protein and Adenovirus Death Protein

  2018influential citation
• Development of Oncolytic Adenoviruses for the Management of Prostate Cancer

  2018cites this paper
• Regulatory signaling network in the tumor microenvironment of prostate cancer bone and visceral organ metastases and the development of novel therapeutics

  2018cites this paper
• INHIBITION OF TUMIOR GROWTH AND NVASION BY ANT MATRIX METALLOPROTEINASE DNAZYMES

  2017cites this paper
• Current status of clinical trials assessing oncolytic virus therapy for urological cancers

  2017cites this paper
• Difference in toxicity reporting between patients and clinicians during systemic chemotherapy in patients with urothelial carcinoma

  2017cites this paper
• The oncolytic adenoviral AdΔΔ mutant sensitizesprostate cancercellsto mitoxantroneby promoting apoptosis and attenuating autophagy

  2017cites this paper
• Oncolytic virotherapy for urological cancers

  2016cites this paper
• Enhancing the neutrophil-mediated anti-cancer response after oncolytic measles virus therapy in B cell malignancy: dissecting out the mechanism

  2016cites this paper
• Targeting of viral vectors for cancer gene therapy

  2016cites this paper
• Polymeric oncolytic adenovirus for cancer gene therapy.

  2015cites this paper
• Genetic Engineering of Oncolytic Viruses for Cancer Therapy

  2015cites this paper
• Gene therapy targeting hepatocellular carcinoma by a dual-regulated oncolytic adenovirus harboring the focal adhesion kinase shRNA.

  2015cites this paper
• TMPRSS2 promoter driven enzyme-prodrug therapy for the treatment of PCa

  2015cites this paper
• Prostate cancer relevant antigens and enzymes for targeted drug delivery.

  2014cites this paper
• Estratègies de millora de la potència antitumoral dels adenovirus oncolítics basades en l’increment de l’alliberament viral i l’extravasació vascular

  2013cites this paper
• Selectively Replicating Oncolytic Adenoviruses Combined with Chemotherapy, Radiotherapy, or Molecular Targeted Therapy for Treatment of Human Cancers

  2013cites this paper
• Anti-Tumor Activity of a miR-199-dependent Oncolytic Adenovirus

  2013cites this paper
• Comparison of Prostate-Specific Promoters and the Use of PSP-Driven Virotherapy for Prostate Cancer

  2013cites this paper
• Selective Replicating Viral Vectors

  2012cites this paper
• Oncolytic Viruses in the Treatment of Cancer: A Review of Current Strategies

  2012cites this paper
• Cancer Targeting Gene-Viro-Therapy and Its Promising Future: A Trend in Both Cancer Gene Therapy and Cancer Virotherapy

  2012cites this paper
• A Single Therapeutic miRNA Rescues the Oncolysis of Androgen Activated Prostate Specific Virus in Androgen Independent Cell Model

  2012cites this paper
• Oncolytic viruses for induction of anti-tumor immunity.

  2012cites this paper
• Clinical development directions in oncolytic viral therapy

  2011cites this paper
• Conditionally replicating adenovirus therapy utilizing bone sialoprotein promoter (Ad-BSP-E1a) in an in vivo study of treating androgen-independent intraosseous prostate cancer.

  2011cites this paper
• Armoring CRAds with p21/Waf-1 shRNAs: the next generation of oncolytic adenoviruses

  2010cites this paper
• 定位表达的新城疫病毒HN蛋白对荷瘤小鼠的抗肿瘤免疫作用

  2010cites this paper
• Oncolytic virus therapy for prostate cancer

  2010cites this paper
• The anti-tumor effect of Newcastle disease virus HN protein is influenced by differential subcellular targeting

  2010cites this paper
• The development of the conditionally replication‐competent adenovirus: replacement of E4 orf1‐4 region by exogenous gene

  2010cites this paper
• A fully replication-competent adenovirus vector with enhanced oncolytic properties

  2010cites this paper
• Viral-based gene delivery and regulated gene expression for targeted cancer therapy

  2010cites this paper
• Gene Therapy for Prostate Cancer

  2010cites this paper
• Oncolytic adenoviruses expressing interleukin: a novel antitumour approach

  2010cites this paper
• Identifying FoxA1 interacting partners : insight into androgen regulated prostatic genes.

  2010cites this paper
• Use of a Bioamplification Assay to Detect Nonselective Recombinants and Assess the Genetic Stability of Oncolytic Adenoviruses

  2010influential citation
• Replication-Competent Ad11p Vector (RCAd11p) Efficiently Transduces and Replicates in Hormone-Refractory Metastatic Prostate Cancer Cells

  2009cites this paper
• Antitumor Activity of Ad-IU2, a Prostate-Specific Replication-Competent Adenovirus Encoding the Apoptosis Inducer, TRAIL

  2009cites this paper
• Transcriptionally regulated, prostate-targeted gene therapy for prostate cancer.

  2009cites this paper
• Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis.

  2009cites this paper
• An oncolytic adenovirus expressing granulocyte macrophage colony-stimulating factor shows improved specificity and efficacy for treating human solid tumors

  2009cites this paper
• Transporte de adenovirus oncolítico canino mediado por células tumorales para el tratamiento de osteosarcoma canino

  2009cites this paper
• Prostate cancer targeting using replication-selective adenoviruses in combination with phytochemicals

  2009cites this paper
• INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies

  2009cites this paper
• Designing adenoviral vectors for tumor-specific targeting.

  2009cites this paper
• Emerging Treatment Modalities II: Gene Therapy for Meningiomas

  2009cites this paper
• Oncolytic adenoviruses for treatment of ovarian cancer

  2009cites this paper
• A multiscale mathematical model for oncolytic virotherapy.

  2009cites this paper
• Anti-tumor and Radio-sensitizing Properties of Ad-IU2, A Prostate-specific Replication-competent Adenovirus Armed with TRAIL

  2008cites this paper
• Macrophage depletion combined with anticoagulant therapy increases therapeutic window of systemic treatment with oncolytic adenovirus.

  2008cites this paper
• IMMUNO-GENE THERAPY FOR METASTATIC PROSTATE CANCER

  2008cites this paper
• Environmental risk assessment of replication competent viral vectors in gene therapy trials

  2008cites this paper
• Increased therapeutic efficacy of the prostate-specific oncolytic adenovirus Ad[I/PPT-E1A] by reduction of the insulator size and introduction of the full-length E3 region

  2008cites this paper
• Comparison of the E3 and L3 regions for arming oncolytic adenoviruses to achieve a high level of tumor-specific transgene expression

  2008cites this paper
• The promise of immunotherapy in prostate cancer: from concept to reality

  2008cites this paper
• Androgen receptor attenuation of Ad5 replication: implications for the development of conditionally replication competent adenoviruses.

  2007cites this paper
• Advances in preclinical investigation of prostate cancer gene therapy.

  2007cites this paper
• Targeting of a conditionally replicative adenovirus agent to human squamous cell carcinomas of the head and neck.

  2007cites this paper
• Gene Therapy for Advanced Prostate Cancer

  2007cites this paper
• Combining adenoviral oncolysis with temozolomide improves cell killing of melanoma cells

  2007cites this paper
• Combining radiation and cancer gene therapy: a potential marriage of physical and biological targeting?

  2007cites this paper
• Efficacy, Toxicity, and Immunogenicity of Adenoviral Vectors

  2007cites this paper
• Targeting lung cancer using an infectivity enhanced CXCR4-CRAd.

  2007cites this paper
• Adenovirus-mediated CD 40 Ligand Immunotherapy of Prostate and Bladder Cancer

  2007cites this paper
• Advances in Prostate Cancer Immunotherapies

  2007cites this paper
• Adenovirus-mediated CD40 ligand immunotherapy of prostate and bladder cancer.

  2007cites this paper
• Treatment of ovarian cancer with a novel dual targeted conditionally replicative adenovirus (CRAd).

  2007cites this paper
• Oncolytic viruses driven by tumor-specific promoters.

  2007cites this paper
• A Novel Chromogranin-A Promoter-Driven Oncolytic Adenovirus for Midgut Carcinoid Therapy

  2007cites this paper
• Conditionally replicating adenoviruses for cancer treatment.

  2007cites this paper
• Gene and Viral Therapy

  2007cites this paper
• Gene delivery and gene therapy of prostate cancer

  2006cites this paper
• CG0070, a Conditionally Replicating Granulocyte Macrophage Colony-Stimulating Factor–Armed Oncolytic Adenovirus for the Treatment of Bladder Cancer

  2006cites this paper
• Viral gene therapy strategies: from basic science to clinical application

  2006cites this paper
• Phase II Evaluation of Docetaxel Plus Exisulind in Patients With Androgen Independent Prostate Carcinoma

  2006cites this paper
• Replicating Viruses for Brain Tumor Treatment

  2006cites this paper
• Selective replication of E1B55K-deleted adenoviruses depends on enhanced E1A expression in cancer cells

  2006cites this paper
• Specific targeting of gene therapy to prostate cancer using a two-step transcriptional amplification system.

  2006cites this paper
• A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.

  2006cites this paper
• Reovirus and other oncolytic viruses for the targeted treatment of cancer

  2006cites this paper
• An oncolytic conditionally replicating adenovirus for hormone-dependent and hormone-independent prostate cancer

  2006cites this paper
• Gene Therapy and Novel Clinical Trial Design

  2006cites this paper
• Development of novel E1-complementary cells for adenoviral production free of replication-competent adenovirus.

  2006cites this paper
• Particules adénovirales ayant une protéine s adénovirale chimérique, et utilisation et procédés de production de ces particules

  2006cites this paper
• Award Number: W81XWH-04-1-0168 TITLE: PSES-A Novel Prostate Specific Chimeric Enhancer for Prostate Cancer Gene Therapy

  2006influential citation